These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16782375)

  • 1. Revisiting asthma control: how should it best be defined?
    Hanania NA
    Pulm Pharmacol Ther; 2007; 20(5):483-92. PubMed ID: 16782375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asthma control: a new perspective on the management of asthma.
    Hanania NA
    Curr Opin Pulm Med; 2009 Jan; 15(1):1-3. PubMed ID: 19077698
    [No Abstract]   [Full Text] [Related]  

  • 3. Suitability of forced expiratory volume in 1 second/forced vital capacity vs percentage of predicted forced expiratory volume in 1 second for the classification of asthma severity in adolescents.
    van Dalen C; Harding E; Parkin J; Cheng S; Pearce N; Douwes J
    Arch Pediatr Adolesc Med; 2008 Dec; 162(12):1169-74. PubMed ID: 19047545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
    Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
    Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limitations of questioning asthma to assess asthma control in general practice.
    Hagmolen Of Ten Have W; van den Berg NJ; van der Palen J; van Aalderen WM; Bindels PJ
    Respir Med; 2008 Aug; 102(8):1153-8. PubMed ID: 18573649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial).
    Bjermer L; Bisgaard H; Bousquet J; Fabbri LM; Greening A; Haahtela T; Holgate ST; Picado C; Leff JA
    Respir Med; 2000 Jun; 94(6):612-21. PubMed ID: 10921768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between fluctuations in lung function and asthma control in two populations with differing asthma severity.
    Thamrin C; Nydegger R; Stern G; Chanez P; Wenzel SE; Watt RA; FitzPatrick S; Taylor DR; Frey U
    Thorax; 2011 Dec; 66(12):1036-42. PubMed ID: 21602542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Airway obstruction lability helps distinguish levels of disease activity in asthma.
    Greenberg S; Liu N; Kaur A; Lakshminarayanan M; Zhou Y; Nelsen LM; Smugar SS; Noonan G; Reiss TF; Knorr BA
    Respir Med; 2012 Apr; 106(4):500-7. PubMed ID: 22301379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between clinical classification, PEF and FEV1: guidelines and reality.
    Palma-Carlos AG; Palma-Carlos ML
    Eur Ann Allergy Clin Immunol; 2003 Apr; 35(4):130-2. PubMed ID: 12793116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting response to therapy in acute asthma.
    Rodrigo GJ
    Curr Opin Pulm Med; 2009 Jan; 15(1):35-8. PubMed ID: 19077703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciclesonide is more effective than budesonide in the treatment of persistent asthma.
    Ukena D; Biberger C; Steinijans V; von Behren V; Malek R; Weber HH; Beck E; Linnhoff A
    Pulm Pharmacol Ther; 2007; 20(5):562-70. PubMed ID: 16962345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.
    Dahlén SE; Malmström K; Nizankowska E; Dahlén B; Kuna P; Kowalski M; Lumry WR; Picado C; Stevenson DD; Bousquet J; Pauwels R; Holgate ST; Shahane A; Zhang J; Reiss TF; Szczeklik A
    Am J Respir Crit Care Med; 2002 Jan; 165(1):9-14. PubMed ID: 11779723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classifying asthma.
    Graham LM
    Chest; 2006 Jul; 130(1 Suppl):13S-20S. PubMed ID: 16840364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients' experience of asthma control and clinical guidelines: perspectives from a qualitative study.
    Rudell K; Hareendran A; Bonner N; Arbuckle R; Burbridge C; Abetz L
    Respir Med; 2012 Jun; 106(6):909-11. PubMed ID: 22361503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adequacy of control of asthma in a general practice. Is maximum peak expiratory flow rate a valid index of asthma severity?
    Morris NV; Abramson MJ; Strasser RP
    Med J Aust; 1994 Jan; 160(2):68-71. PubMed ID: 8309371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What are the determinates of asthma control?
    Chipps BE; Spahn JD
    J Asthma; 2006 Oct; 43(8):567-72. PubMed ID: 17050219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial.
    Price DB; Swern A; Tozzi CA; Philip G; Polos P
    Allergy; 2006 Jun; 61(6):737-42. PubMed ID: 16677244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asthma control test (ACT): comparison with clinical, functional, and biological markers of asthma control.
    Melosini L; Dente FL; Bacci E; Bartoli ML; Cianchetti S; Costa F; Di Franco A; Malagrinò L; Novelli F; Vagaggini B; Paggiaro P
    J Asthma; 2012 Apr; 49(3):317-23. PubMed ID: 22401649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of the effect of yoga training on pulmonary functions in patients with bronchial asthma.
    Sodhi C; Singh S; Dandona PK
    Indian J Physiol Pharmacol; 2009; 53(2):169-74. PubMed ID: 20112821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily evening administration of mometasone furoate in asthma treatment initiation.
    Bensch GW; Prenner B; Berkowitz R; Galant S; Ramsdell J; Lutsky B
    Ann Allergy Asthma Immunol; 2006 Apr; 96(4):533-40. PubMed ID: 16680923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.